Percentage of free to total <scp>PSA</scp> as a biomarker of survival in metastatic castration‐resistant prostate cancer
An elevated %fPSA appears to be an adverse prognostic biomarker. Findings are consistent with biochemical recurrence studies, suggesting a biological basis. Validation and mechanistic studies are warranted.
Authors
- Neil Fleshner (ORCID: https://orcid.org/0000-0001-7407-7463)
- Alexandre R. Zlotta (ORCID: https://orcid.org/0000-0003-2315-5809)
- Jaime O. Herrera‐Cáceres (ORCID: https://orcid.org/0000-0001-6793-4404)
- Hina Shiakh
- Andrew W. Silagy (ORCID: https://orcid.org/0000-0002-4990-8445)
- Louise Kostos (ORCID: https://orcid.org/0000-0001-6072-5175)
- Eleftherios Diamantis
- Marian S. Wettstein (ORCID: https://orcid.org/0000-0003-1378-3625)
- Hanan Goldberg (ORCID: https://orcid.org/0000-0002-5777-2138)
- Ting Wai Yiu (ORCID: https://orcid.org/0000-0002-5551-9817)
- Rui Bernardino (ORCID: https://orcid.org/0000-0001-8076-4550)
- Dixon Woon (ORCID: https://orcid.org/0000-0002-4398-8341)
- Damien Bolton
- Gregory J. Nason
Institutions
- The University of Melbourne (AU)
- University of Toronto (CA)
- SUNY Upstate Medical University (US)
- Peter MacCallum Cancer Centre (AU)
- Austin Health (AU)
Publication Details
- Journal
- British Journal of Urology
- Published
- 2025-04-25
- DOI
- https://doi.org/10.1111/bju.16751
- Citations
- 1
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 1.52
Funders
- University of Melbourne